MIR494

1. MIR494 inhibits PTEN in mouse cells.

   “Luciferase reporter assay demonstrated that miR-494-3p targeted phosphatase and tensin homolog (PTEN)”

   Cellsin vitro

   Down-expression of miR-494-3p in senescent osteocyte-derived exosomes inhibits osteogenesis and accelerates age-related bone loss via PTEN/PI3K/AKT pathway

   Bone & joint research·Feb 1, 2024

More on PTEN

1. MIR494 decreases bone loss in mice.

   “The upregulation of exosomal miR-494-3p by miRNA mimics attenuated the effects of senescent MLO-Y4 cell-derived exosomes on osteogenic differentiation.”

   Animalsin senescent MLO-Y4 cell-derived exosomesbone

   Down-expression of miR-494-3p in senescent osteocyte-derived exosomes inhibits osteogenesis and accelerates age-related bone loss via PTEN/PI3K/AKT pathway

   Bone & joint research·Feb 1, 2024

1. MIR494 improves endothelial barrier function in human cells.

   “Overexpression of miRNA-370 or -494 partially rescued the MEG8-silencing-induced barrier loss.”

   CellsMEG8 silencing in HUVECshuman umbilical vein endothelial cells

   The long non-coding RNA MEG8 induces an endothelial barrier through regulation of microRNA-370 and -494 processing

   Journal of cell science·May 26, 2022

1. MIR494 predicts HbA1c in humans (β = -0.47; 95% CI: -0.67 to -0.21).

   “An increase in miR-494-3p predicted larger HbA1c reductions at 12 weeks (β = -0.47; 95% CI: -0.67 to -0.21)”

   Human trialat 12 weeks in adults with type 2 diabetes on a low-calorie diet12 weeksn = 16

   Early changes in exosomal microRNAs after a one-week low-calorie diet predict sustained glycaemic and weight outcomes in patients with type 2 diabetes

   Food & function·Sep 16, 2025

More on HbA1c